Ketamine Research Guide
Full name: Ketamine (and esketamine)
A dissociative anesthetic that, at lower doses, produces psychedelic-like effects and rapid relief from severe depression. The nasal-spray form esketamine is FDA-approved for treatment-resistant depression.
How Ketamine Works
Blocks NMDA glutamate receptors, which is thought to quickly boost synaptic connections and lift mood. This is a different pathway from classic serotonin psychedelics.
Dosing Protocol
- Typical dose: Low sub-anesthetic doses for depression (clinic-administered)
- Frequency: A series of supervised sessions
- Duration: Acute effects last ~40-90 minutes
- Route: IV infusion, intramuscular, or nasal spray (esketamine)
Reported Benefits
- Rapid relief from treatment-resistant depression
- FDA-approved option (esketamine) exists
- Can reduce suicidal thoughts quickly
- Useful when other antidepressants fail
Potential Side Effects
- Dissociation and confusion
- Raised blood pressure
- Nausea
- Bladder problems with heavy long-term use
- Abuse potential
Research Citations
- Esketamine nasal spray for treatment-resistant depression (2019) - Pivotal trials supported FDA approval, showing reduced depression symptoms when added to an oral antidepressant.
- IV ketamine for depression and suicidal ideation (2018) - Single infusions produced rapid, though often short-lived, reductions in depression and suicidal thoughts.
Related Psychedelics Compounds
View full Ketamine profile with 3D molecule viewer →